Sign in Subscribe
International cooperation

Indonesia Reaffirms Leadership in Global Health Diplomacy

Strategic Insights

— 1 min read

Indonesia has played a pivotal role in ensuring equitable access to safe, high-quality, and affordable vaccines through its strategic and sustained participation in the Developing Countries Vaccine Manufacturers' Network (DCVMN). As a key driver in advancing vaccine self-reliance and public health capacity in developing countries, PT Bio Farma (Persero) has been a cornerstone of Indonesia's commitment to global health diplomacy. The 26th DCVMN Annual General Meeting, held in Bali on 29-31 October, marks a moment for Indonesia to reaffirm its leadership in this arena.

Key Takeaways:

  • PT Bio Farma (Persero) has been a founding member of DCVMN since its inception in 2000, collaborating on vaccine self-reliance and public health capacity in developing countries.
  • Bio Farma has played a vital role in expanding access to the pentavalent (DPT-HepB-Hib) vaccine through a technology-transfer collaboration with the Netherlands Vaccine Institute in 2004.
  • Indonesia's leadership in the global health landscape was further recognized when Bio Farma was entrusted to serve as Chair of the Board of DCVMN for the 2023-2025 period, showcasing Indonesia's capacity to lead the vaccine industry in developing countries.
  • Bio Farma's commitment to innovation was reflected in its nOPV2 vaccine receiving an Emergency Use Listing from the World Health Organization in 2020, marking a significant milestone in technological self-reliance and global confidence in Indonesia's capability to contribute to international health security.
  • As the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution, Bio Farma continues to strengthen Indonesia's strategic role in the global health landscape.
  • Bio Farma supplies vaccines to over 150 countries and holds WHO Prequalification certification for 12 types of vaccines.

Statistics:

  • 26th DCVMN Annual General Meeting will take place in Bali on 29-31 October 2025.
  • DCVMN has 46 member vaccine manufacturers from 17 developing countries.
  • Bio Farma produces over 3.5 billion vaccine doses per year.
  • Bio Farma's nOPV2 vaccine received an Emergency Use Listing from the World Health Organization in 2020.
  • Bio Farma holds WHO Prequalification certification for 12 types of vaccines.

Sources:

  • DCVMN (dcvmn.org)
  • PT Bio Farma (Persero) (www.biofarma.co.id)
  • ACN Newswire (copyright 2025, all rights reserved)
  • Developing Countries Vaccine Manufacturers' Network (DCVMN)
  • World Health Organization (WHO)
  • Organization of Islamic Cooperation (OIC)

Read more